Broad Spectrum Anticancer Activity of Pistagremic Acid
- *Corresponding Author:
- Ghias Uddin
Institute of Chemical Sciences
University of Peshawar
E-mail: [email protected], [email protected]
Received Date: July 31, 2013; Accepted Date: August 17, 2013; Published Date: August 26, 2013
Citation: Uddin G, Rauf A, Siddiqui BS, Khan A, Marasini BP, et al. (2013) Broad Spectrum Anticancer Activity of Pistagremic Acid. Chemotherapy 2:117. doi: 10.4172/2167-7700.1000117
Copyright: © 2013 Uddin G, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Background: Pistagremic acid; 3-methyl-7-(4,4,10,13,14-pentamethyl-3-2,3,4,5,6,7,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthr-en-17-yl)-oct-3-enoic acid was isolated from the chloroform fraction of Pistacia integerrima. Cytotoxic evaluation against NCI-60 DTP human tumor cell line was performed.
Methods: The anticancer assays for this compound were performed in accordance with the protocol of the Drug Evaluation Branch, by the National Cancer Institute (NCI) Developmental Therapeutic Program (www.dtp.nci.nih.gov) to be screened for their anticancer activity in vitro.
Results: It showed broad spectrum antiproliferative activity with an average GI50, and TGI, values 0.103 μM and 0.259 μM, respectively. It also showed significant LC50 value at the average 0.634 μM against all cell lines excluding K-562, RPMI-8226, NCI-H226, and NCI-H460 cell-lines.
Conclusions: Pistagremic acid showed cytotoxicity for all tested cancer cell line, thus it may serve as a potential structure lead for the development of new anticancer drugs.